Company Description (as filed with the SEC)
Biota is a leading anti-infective drug development company, based in Rockville, Maryland, with key expertise in respiratory diseases, particularly influenza. Biota developed its first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza(TM). Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota also has an advanced program for the treatment of human rhinovirus (HRV) infection, with a successfully completed Phase IIb study in asthmatic subjects. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product, laninamivir, is approved and marketed as lnavir(R) in Japan. Biota also holds a contract from the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA. ... More ...